New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 4, 2014
08:55 EDTTKMRTekmira volatility expected to move, FDA "stands ready" to work on Ebola
Tekmira volatility expected to move as the FDA said it “stands ready” to work with companies and investigators working with patients in “dire need of treatment” for the Ebola virus, Reuters says. Overall option implied volatility of 103 compares to its 14-week average of 99 according to Track Data, suggesting large price movement.
News For TKMR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 22, 2014
09:03 EDTTKMRTekmira announces agreement to provide TKM-Ebola-Guinea for clinical studies
Tekmira Pharmaceuticals announced that the company has entered into a Manufacturing and Clinical Trial Agreement with the University of Oxford to provide the new TKM-Ebola-Guinea therapeutic product for clinical studies in West Africa. The studies are expected to commence early next year, subject to finalization of a suitable clinical protocol. The University of Oxford is the representative of the International Severe Acute Respiratory and Emerging Infection Consortium, or ISARIC. ISARIC will conduct clinical studies of TKM-Ebola-Guinea in Ebola virus infected patients, with funding provided by the Wellcome Trust. GMP manufacture of TKM-Ebola-Guinea is now complete and 100 treatment courses are available for the study.
08:48 EDTTKMRTekmira receives clearance to conduct Phase I clinical study with TKM-HBV
Tekmira Pharmaceuticals announced that it has received a No Objection Letter from Health Canada regarding its Clinical Trial Application, allowing the Company to proceed with a Phase I clinical trial with TKM-HBV, a therapeutic agent designed to treat patients chronically infected with hepatitis B virus, or HBV. The company expects to commence a single ascending dose Phase I trial with TKM-HBV in healthy human volunteers in 1Q15, and progress to chronically infected patients in a multi-dosing regimen in the second half of 2015.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use